Health Canada's New 90-Day Limit on NOD and NON Extensions for Generic Drugs: A Response Plan for Sponsors

On 1 September 2026, Health Canada reset the clock for generic drug sponsors. Three notices published on the same day, under file number 26-105134-755, together change how long you have to answer a deficiency letter, what happens to backlog files stuck in Review 2, and which submissions move to the front of the queue. The most consequential of the three sets a hard limit: one extension request per notice, up to 90 days, for a total response window of 180 days. If you cannot provide a complete response in time, the submission can be cancelled or withdrawn.

If you hold an open Notice of Deficiency (NOD) or Notice of Non-Compliance (NON), this is not a policy to read next quarter. Per the Health Canada extension notice, the change applies to every extension request received as of 1 September 2026. This article explains exactly what changed, how the 180-day rule works, what a NOD-W or NON-W means for your file, and how to build a complete, high-quality response before the window closes.

Executive Summary

Health Canada has returned to a more structured approach for granting extensions on generic drug submissions. Sponsors now get the standard 90 days to respond to an NOD or NON, plus one extension request of up to 90 days, for a maximum of 180 days. If a complete response is not filed inside that window, the sponsor can cancel the submission, or Health Canada may issue an NOD-withdrawal (NOD-W) or NON-withdrawal (NON-W). A second, related notice changes how backlog submissions already in Review 2 are handled, allowing a targeted request for additional safety, efficacy or quality information instead of an automatic withdrawal. A third notice confirms that submissions addressing drug shortage risk, and non-authorized generics where no generic exists, will be prioritized in the review queue. Health Canada states plainly that it is currently not meeting performance standards for some submissions.

The Three 1 September 2026 Notices at a Glance

All three notices share file number 26-105134-755 and were issued on 1 September 2026. Read together, they form a single message: respond completely, respond on time, and expect Health Canada to protect the drug supply first.

Notice	What it does	Who it affects
Revised approach to extensions	Limits sponsors to one extension request per NOD or NON, up to 90 days, for a 180-day total response period	All open and future NOD or NON responses for generic submissions
Additional information in Review 2	Allows a targeted request for more safety, efficacy or quality information for certain backlog files instead of automatic withdrawal	Backlog ANDS and SANDS already past the NON response stage
Prioritizing generic submissions	Moves shortage-mitigating and non-authorized generic submissions to the front of the review queue	New and in-queue generic submissions

What Changed on 1 September 2026?

Health Canada tightened the rules for extending deficiency-response deadlines on generic drug submissions. The core change: one extension request per notice, capped at 90 days. Combined with the standard 90-day response period, a sponsor now has at most 180 days to answer an NOD or NON. This matters because a missed deadline no longer drifts. It can end the submission through an NOD-W or NON-W, forcing a refile and a return to the back of the queue. Sponsors should map every open deficiency letter to a firm internal deadline immediately.

A Notice of Deficiency (NOD) is issued during the scientific review when deficiencies or significant omissions prevent the review from continuing, so the review is not yet complete when it is sent. A Notice of Non-Compliance (NON) is issued after the scientific review, when Health Canada finds the submission incomplete or non-compliant with the Food and Drugs Act and its regulations. Both stop the clock and put the burden back on the sponsor. Before this change, extension practice was looser and less predictable. Health Canada describes the new approach as a return to structure, tied directly to workload pressures and a growing backlog of generic files.

How the New Extension Rule Works

The rule is simple to state and unforgiving in practice. You have 90 days to respond to an NOD or NON under the standard process. You may request one extension of up to 90 days. That is the ceiling: 180 days total, one extension, per notice. Health Canada reviews and approves extension requests case by case, so an extension is a request, not a right. Plan your response as though the standard 90 days is all you have, and treat the extension as contingency, not schedule.

The 90 Plus 90 Timeline

Think of the response window as two blocks. The first is the standard 90 days that begins when the notice is issued. The second is a single extension of up to 90 days that you must request and that Health Canada must grant. If you cannot provide a complete response by the end of the total period, you can cancel the submission yourself. Otherwise, Health Canada may issue an NOD-W or NON-W, as applicable. You may refile the submission when you can provide complete information.

Two operational points are easy to miss. First, submission requirements under the regulations and the pause-the-clock provisions continue to apply, so the interplay between a formal extension and a clock pause needs to be managed deliberately, not assumed. Second, Health Canada encourages sponsors to engage early if they anticipate trouble meeting a timeline. Early engagement is now part of the expected behaviour, not a courtesy.

What NOD-W and NON-W Mean for Your File

An NOD-W or NON-W is a withdrawal of the submission for failure to respond completely within the allowed period. It is not a rejection on scientific merit, and it does not bar you from the market permanently, but it does end the current review. To return, you refile once you can provide complete information, which means re-entering the queue. For a product tied to a shortage or a launch window, that delay carries real commercial and patient-access cost. The takeaway is blunt: the cheapest response is the one filed complete and on time the first time.

The Review 2 Backlog Policy: A Second Chance, Not a Reset

Review 2 is the stage of review after a sponsor has responded to an NON. Under the backlog notice, Health Canada may, for certain backlog submissions already in Review 2, request additional safety, efficacy or quality information or material rather than move straight to withdrawal. This is done under section C.08.004 of the Food and Drug Regulations. It gives sponsors a targeted opportunity to close the gap, but it is not a licence to expand the file.

The limits are strict. At this stage sponsors cannot make major changes, such as adding a new indication or a new route of administration. Those are major changes that require a new submission or supplement. Health Canada will accept only information or material directly related to its additional-information request, and it may issue an NON-W if the response is insufficient. The notice also states that this flexibility should not be viewed as establishing a practice that will apply to future submissions, and it does not change the scientific standards that must be met.

Prioritization: Which Submissions Move Up the Queue

The third notice sets out how Health Canada is prioritizing generic reviews. Per the prioritization notice, priority goes to generic submissions that can meaningfully help address potential harms from drug shortages, and to non-authorized generic submissions where there is no authorized generic version of the drug in Canada. Prioritization affects only the order in which eligible submissions are reviewed first. It does not change the scientific review, the regulatory requirements, the evidentiary standards, or the final decision, and it does not guarantee authorization.

Health Canada is separately consulting on a pilot to prioritize certain generic submissions involving domestic manufacturing within the review queue. That pilot would not create a separate approval pathway or lower regulatory requirements. We cover it in detail in our guide to the generic prioritization domestic manufacturing pilot. Sponsors with a shortage-mitigating product should document that link clearly, because prioritization is only useful if the reviewer can see why the file qualifies.

Who Is Affected and What Is in Scope

The extension rule applies to abbreviated new drug submissions (ANDS), supplemental abbreviated new drug submissions (SANDS), applications for drug identification numbers (DINs), and all extension requests received as of the date of the notice. If your file falls into any of these categories and you receive or are already holding an NOD or NON, the 180-day ceiling applies. The Review 2 backlog policy is narrower: it targets certain backlog ANDS and supplements to ANDS already in Review 2, with DIN applications considered case by case.

Submission type	Extension rule (180-day cap)	Review 2 backlog policy
ANDS	Applies	Applies to certain backlog files
SANDS / supplements to ANDS	Applies	Applies to certain backlog files
DIN applications	Applies	Considered case by case
Extension requests received on or after 1 Sep 2026	Applies	Not applicable

Building a Complete Response Inside 180 Days

A deficiency response fails for predictable reasons: it answers some questions and not others, it introduces new data that raise fresh questions, or it arrives late. The discipline that beats the 180-day clock is the same discipline that survives a Health Canada inspection. Treat the deficiency letter as a scope document, close every item with traceable evidence, and control the schedule from day one. Here is a practical sequence.

Deconstruct the notice. List every deficiency as a discrete, numbered item and assign an owner, a data source, and a due date to each. Nothing is complete until every item has a documented answer.
Run a gap assessment in the first two weeks. Decide early where you have the data, where you must generate it, and where a targeted study or additional stability time point is required. Generating data is what consumes the 180 days.
Stay inside the question. Provide only information directly responsive to each deficiency. Do not add a new indication, a new route, or unrelated changes, which become major changes and restart the process.
Apply CAPA thinking to quality deficiencies. For a specification, method, or stability gap, correct the immediate finding and address the root cause, so the response holds up and the same issue does not recur at Review 2.
Decide on the extension deliberately. If the standard 90 days is not enough, request the single extension early with a clear justification, and remember Health Canada grants it case by case.
Engage early if you foresee a problem. Health Canada explicitly invites early contact with the Bureau of Pharmaceutical Sciences when a timeline is at risk. Silence is the worst option.

The same response discipline that closes a deficiency letter also closes an inspection observation. Our guide on responding to an FDA Form 483 or Health Canada inspection observation sets out how to structure a defensible, root-cause-based response under time pressure.

Compliance Checklist

Use this checklist the day an NOD or NON lands, and again before you file the response.

Record the notice date and calculate the standard 90-day deadline and the maximum 180-day deadline.
Break the notice into a numbered deficiency register with an owner and due date for each item.
Complete a gap assessment within two weeks to identify data you must generate.
Confirm every response element is directly responsive and introduces no major change.
Decide whether to request the single 90-day extension, and file the request early with justification.
Manage pause-the-clock provisions and the extension together, not in isolation.
Apply CAPA and root-cause analysis to every quality deficiency before responding.
Engage the Bureau of Pharmaceutical Sciences early if a timeline is at risk.
If the product mitigates a shortage or is a non-authorized generic, document the basis for prioritization.

Common Mistakes

Assuming extensions are routine. The single 90-day extension is granted case by case and is capped. Planning around it as guaranteed schedule is the fastest route to a withdrawal.
Answering only the easy deficiencies. A partial response is an incomplete response, and an incomplete response at the deadline can trigger an NOD-W or NON-W.
Expanding the file at Review 2. Adding a new indication or route is a major change that forces a new submission and loses your place.
Starting data generation late. Stability, method validation and additional studies take time the clock does not give back. Identify them in the first two weeks.
Going silent. Health Canada expects early engagement when a timeline is at risk. Waiting until the deadline removes every option.

Frequently Asked Questions

How long do I have to respond to a Notice of Deficiency from Health Canada?

For generic drug submissions, you have a standard 90 days to respond. As of 1 September 2026 you may request one extension of up to 90 days, for a maximum total of 180 days. Extensions are approved case by case.

What is the difference between a NOD and a NON?

What happens if I miss the response deadline?

If you cannot provide a complete response within the total period, you can cancel the submission, or Health Canada may issue an NOD-withdrawal (NOD-W) or NON-withdrawal (NON-W). You may refile the submission once you can provide complete information, which means re-entering the review queue.

Does the new rule apply to submissions already under review?

Yes. The extension rule applies to ANDS, SANDS and DIN applications, and to all extension requests received as of 1 September 2026, so open files are covered. The separate Review 2 backlog policy applies to certain backlog ANDS and supplements already past the NON response stage.

Can I add a new indication when I respond at Review 2?

No. At Review 2 you cannot make major changes such as adding a new indication or route of administration. Health Canada will accept only information directly related to its additional-information request. A major change requires a new submission or supplement.

Which generic submissions get prioritized?

Health Canada prioritizes generic submissions that can meaningfully help address drug shortage harms, and non-authorized generics where no authorized generic version exists in Canada. Prioritization sets review order only; it does not change scientific standards or guarantee authorization.

How MFLRC Can Help

A 180-day window is manageable with a plan and unforgiving without one. MFLRC provides senior-led regulatory affairs, licensing and import and export support built around deficiency response. We triage your NOD or NON, convert it into a numbered response plan, run a gap assessment, and manage the schedule against the standard and extended deadlines so nothing slips.

Our quality assurance team builds the specification, method and stability data packages that answer quality deficiencies, and our audit team runs a pre-submission data-integrity check so your response holds up under scrutiny. For sponsors managing supply risk, we align the deficiency response with your shortage strategy, including drug shortage obligations for market authorization holders and the exceptional importation pathway, so a delay in one file does not become a shortage on the shelf.

Quality failures in the generic space are not hypothetical, as our review of recent generic GLP-1 quality failures shows. Strong quality systems are the best defence against a deficiency in the first place, and our Health Canada GMP inspection-readiness self-assessment is a good place to start.

Holding an open NOD or NON? MFLRC can triage your deficiency letter and build a complete response inside the 180-day window. Book a consultation.

Book a Consultation

Conclusion

Health Canada has made the message clear: complete responses, filed on time, are now the price of staying in the queue. The 180-day ceiling, the narrow Review 2 flexibility, and the shortage-first prioritization all point the same way. Sponsors who treat every deficiency letter as a scoped, owned, root-cause-driven project will keep their files alive; those who rely on open-ended extensions will lose them. Pair this Canadian rule with a clear view of your global pathway, including the choice between an ANDA and a 505(b)(2) route in the United States, and you can plan a portfolio that survives tightening timelines on both sides of the border.